04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
18:25 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Adaptimmune reports zero responses across three T cell therapy trials

Adaptimmune Therapeutics plc (NASDAQ:ADAP) reported that zero of 17 evaluable patients achieved a response across the first two dose cohorts of three Phase I trials evaluating the company's MAGE-A10 and MAGE-A4 SPEAR T cell therapies...
22:46 , Oct 22, 2018 |  BC Extra  |  Clinical News

Adaptimmune reports zero responses across three T cell therapy trials

Adaptimmune Therapeutics plc (NASDAQ:ADAP) fell $3.21 (30%) to $7.55 on Monday after reporting that zero of 17 evaluable patients achieved a response across the first two dose cohorts of three Phase I trials evaluating the...
16:50 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Adaptimmune reports Phase I safety data for TCR therapy

Adaptimmune Therapeutics plc (NASDAQ:ADAP) reported safety data from eight evaluable patients receiving 90-100 million cells of its MAGE-A10 SPEAR T cell therapy in two open-label Phase I trials to treat cancer. The data were presented...
19:25 , Sep 8, 2017 |  BC Week In Review  |  Company News

GSK exercises option for Adaptimmune’s NY-ESO SPEAR T cell therapy program

Adaptimmune Therapeutics plc (NASDAQ:ADAP) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exercised a 2014 option for exclusive rights to Adaptimmune’s NY-ESO SPEAR T cell therapy program. The decision comes as Adaptimmune was preparing for a pivotal trial...
00:23 , Sep 8, 2017 |  BC Extra  |  Company News

GSK nabs Adaptimmune’s NY-ESO SPEAR T cell therapy program

Adaptimmune Therapeutics plc (NASDAQ:ADAP) gained $0.81 (12%) to $7.55 Thursday after GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exercised a 2014 option for exclusive rights to Adaptimmune’s NY-ESO SPEAR T cell therapy program. The decision comes as Adaptimmune...
21:41 , Jul 20, 2017 |  BC Innovations  |  Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR -like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

MAGE-A10 SPEAR T-cell therapy: Phase I started

Adaptimmune began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV MAGE A10 TCR in up to 12 patients with an HLA-A*201 or HLA-A*206 allele and tumors expressing MAGEA10. Adaptimmune Therapeutics plc (NASDAQ:ADAP), Abingdon,...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Adaptimmune Therapeutics, University of Texas MD Anderson Cancer Center deal

Adaptimmune and MD Anderson partnered to develop T cell receptor (TCR) cancer therapeutics using Adaptimmune’s Specific Peptide Enhanced Affinity Receptor (SPEAR) technology. The partnership will initially focus on compounds against melanoma-associated antigen A10 (MAGEA10) and...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

MAGE A10 TCR: Phase I/II started

Adaptimmune began an open-label, dose-escalation, international Phase I/II trial to evaluate IV MAGE A10 TCR in up to 32 patients with the HLA-A*0201 and HLA-A*0206 alleles and NSCLC positive for MAGEA10. Adaptimmune Therapeutics plc (NASDAQ:ADAP),...